The invention relates to polymers comprising NOS agonists and one or more monomers selected from the group consisting of lactide, glycolide and epsiloncaprolactone, wherein the NOS agonist is incorporated as repeating monomer units into the body or backbone of the polymer are disclosed. The NOS agonist may comprise one or more carboxylic acid groups and one or more alkylhydroxy groups. In another embodiment, the NOS agonist may comprise a carboxylic acid group and an alkylhydroxy group that can be joined to form a lactone containing cyclic ring. In another embodiment, the NOS agonist comprises HMG CoA reductase inhibitor or statin.
